FDA panel rejects Avastin for breast cancer, but Medicare will still pay for it -- and Provenge

A Food and Drug Administration panel recommended withdrawing Avastin for the treatment of breast cancer, saying studies have failed to prove the drug's effectiveness. The FDA is likely to follow the advisors' recommendation, which would give private insurance companies a reason to stop covering... Roche Holding AG via Bloomberg News
Loading